PeptidesResearchCalculatorSourcesAI Chat

NAD+

NAD+ research profile covering evidence quality, proposed mechanisms, safety considerations, regulatory status, and linked primary sources.

Evidence-led profile

Research snapshot

Evidence stage
Extensive research record
References
5 linked sources
Research coverage
4 areas

Published by the PepGuide Editorial Team using our research methodology.

Overview

NAD+ participates in over 500 enzymatic reactions and is essential for mitochondrial electron transport chain function. Age-related NAD+ decline of 10-50% across tissues has been linked to metabolic dysfunction, neurodegeneration, and accelerated aging.

Mechanism of Action

NAD+ restores cellular energy production through mitochondrial electron transport, activates sirtuins (SIRT1-7) for DNA repair and longevity signaling, and supports PARP-mediated genome maintenance.

  • Mitochondrial Electron Transport: Primary electron carrier in respiratory chain, driving ATP synthesis
  • Sirtuin Activation (SIRT1-7): Essential co-substrate for all seven mammalian sirtuins regulating gene expression and DNA repair
  • PARP-Mediated DNA Repair: Consumed by PARP enzymes to catalyze DNA break repair and genome maintenance
  • CD38 / NAD+ Homeostasis: Counteracts age-related NAD+ depletion driven by increased CD38 activity
  • Circadian Rhythm Regulation: NAD+ oscillations drive SIRT1-mediated regulation of CLOCK/BMAL1

Research

Anti-Aging & Longevity

NAD+ decline of 10-50% during aging. Supplementation restores sirtuin activity and DNA repair.

  • Age-related decline across tissues
  • Sirtuin activation extends lifespan
  • PARP DNA repair restored

Neuroprotection

Reduces neuroinflammation and supports neurotransmitter synthesis.

  • Intranasal NAD+ protected hippocampal neurons in TBI
  • NR-SAFE trial positive in Parkinsons

Metabolic Health

Central to glucose and lipid metabolism via mitochondrial function.

  • NMN RCT: dose-dependent performance improvements
  • Improved insulin sensitivity

Cognitive Enhancement

Supports neuronal energy, synaptic plasticity, and neurotransmitter optimization.

  • Enhanced mitochondrial function in neurons
  • SIRT1 promotes neuronal survival

Safety and Limitations

Start with lower doses (50mg) to evaluate tolerance. IV requires medical supervision. Avoid alcohol during therapy. Refrigerate reconstituted solution and use within 14 days.

Common Side Effects

  • Injection site redness or irritation
  • Mild nausea
  • Warmth or flushing sensation
  • Mild headache

Contraindications

  • Active cancer
  • Pregnancy or breastfeeding
  • Known hypersensitivity to NAD+ or nicotinamide

Drug Interactions

  • Alcohol substantially depletes NAD+ levels — avoid
  • May interact with chemotherapy agents targeting NAD+ metabolism

Uncommon

  • Chest tightness during IV infusion
  • Muscle cramping
  • Lightheadedness

Research protocol summary

Typical Dose
100mg daily (after 2-week ramp-up)
Frequency
Once daily
Route
Subcutaneous injection
Timing
Morning preferred
Cycle Length
8-16 weeks
Break Between Cycles
4-8 weeks
Storage
Refrigerate 2-8°C, use within 14 days
Injection Sites
Abdomen · Thigh · Upper arm

These values summarize cataloged research protocols. They are not personal dosing instructions or medical guidance.

Reconstitution Calculator

Pharmacokinetic Profile

NAD+ — Pharmacokinetic Curve

Subcutaneous injection
0%25%50%75%100%0m45m1.5h2.3h3h3.8hTimeConcentration (% peak)T_max 25mT_1/2 45m
Half-life: 45mT_max: 30mDuration shown: 3.8h

Molecular Structure

2D Structure
NAD+ molecular structure
Molecular Properties
Formula
C21H27N7O14P2
Weight
663.43 Da
Length
2 amino acids
CAS
53-84-9
PubChem CID
5892

Research Indications

Primary

Emerging

Directly restores declining NAD+ levels

Emerging

Supports neuronal energy and neuroprotection

Emerging

Central role in mitochondrial function

Secondary

Emerging

Restores mitochondrial ATP production

Emerging

Early clinical trials in Parkinsons

Emerging

Enhanced mitochondrial recovery

Research Protocols

Subcutaneous Injection

100mg daily subcutaneous injection. Ramp up: 50mg week 1, 75mg week 2, then 100mg daily.

GoalDoseFrequencyDuration
100mgDaily—(After 2-week ramp-up)

Intramuscular Injection

250-500mg IM injection 1-2x weekly. 80-90% bioavailability.

GoalDoseFrequencyDuration
250-500mg1-2x weekly—(Higher single doses)

Intravenous Injection

500-1000mg IV infusion 1-2x weekly. Clinical setting required. 100% bioavailability.

GoalDoseFrequencyDuration
500-1000mg1-2x weekly—(Slow infusion to avoid flushing)

Intranasal Injection

25-50mg intranasal 1-2x daily. Bypasses blood-brain barrier.

GoalDoseFrequencyDuration
25-50mg1-2x daily—(Olfactory/trigeminal pathway)

Interactions

Peptide Interactions

✦
BPC-157synergistic

Enhances cellular repair and energy production

✦
TB-500synergistic

Complementary tissue regeneration and mitochondrial support

✦
Ipamorelinsynergistic

GH pathways benefit from improved cellular energy

✦
L-Carnitinesynergistic

Both target mitochondria via complementary mechanisms

Reported Research Timeline

Week 1-2

Initial energy improvements, enhanced mental clarity, possible mild flushing

Week 3-4

Enhanced physical performance and faster recovery

Week 5-8

Sustained energy, improved sleep quality

Week 9-12+

Optimized metabolic function, cumulative cognitive benefits

Quality Indicators

What to look for

  • White to off-white lyophilized powder
  • Dissolves to clear colorless solution
  • Third-party COA with HPLC purity ≥98%
  • Shipped with cold packs

Caution

  • Yellow tint may indicate degradation
  • Use within 14 days of reconstitution

Red flags

  • Cloudy or discolored solution
  • Visible particles
  • Stored at room temperature
  • No COA available

Frequently Asked Questions

References (5)

  1. [1]
    Won SJ et al. Intranasal NAD+ for traumatic brain injury Journal of Neurotrauma (2012)

    → Protected hippocampal neurons

  2. [2]
    Martens CR et al. Chronic NR supplementation elevates NAD+ Nature Scientific Reports (2019)

    → Safe NAD+ elevation in adults

  3. [3]
    Massudi H et al. Age-associated NAD+ metabolism changes PLoS ONE (2012)

    → NAD+ decreases 10-50% with age

  4. [4]
    Trammell SA et al. NR augments human blood NAD+ Nature Communications (2016)

    → Dose-dependent NAD+ elevation

  5. [5]
    Yi L et al. NMN in middle-aged adults RCT GeroScience (2022)

    → Dose-dependent performance gains

Sources: PubMed, pep-pedia.org, peptidedosages.com

Continue researching NAD+

Keep scientific evidence separate from commercial availability. Review how claims are evaluated, explore question-led research paths, or inspect disclosed source records without changing the editorial conclusions on this page.

Review methodologyExplore research pathsCheck source records

On this page

OverviewMechanism of ActionResearchAnti-Aging & LongevityNeuroprotectionMetabolic HealthCognitive EnhancementSafety and LimitationsResearch Protocol SummaryReconstitution CalculatorPharmacokinetic ProfileMolecular StructureResearch IndicationsResearch ProtocolsInteractionsReported Research TimelineQuality IndicatorsFAQReferencesRelated PeptidesResearch next steps